739 related articles for article (PubMed ID: 21952282)
1. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
2. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
4. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
5. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
6. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
7. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
8. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Lévy F; Colombetti S
Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
[TBL] [Abstract][Full Text] [Related]
9. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
10. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
11. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
12. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
13. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG
Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
[TBL] [Abstract][Full Text] [Related]
14. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
15. DC-based cancer vaccines: lessons from clinical trials.
Brody JD; Engleman EG
Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
[No Abstract] [Full Text] [Related]
16. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
17. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
[TBL] [Abstract][Full Text] [Related]
18. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]